SCHEMBL569768

SCHEMBL569768

COc1ccc(NC(=O)c2cc(-c3ccco3)ccn2)cc1C(=O)NCCCN

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
KLK7 P49862 1/20 0.49
LCLAT1 Q6UWP7 11/20 0.46
MAPT P10636 3/20 0.46
USP2 O75604 1/20 0.44
PTPN7 P35236 1/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.42
GRM4 Q14833 1/20 0.42
CFTR P13569 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL569321 0.87 MEN1 (0.68) MEN1KMT2AKLK7MAPTKDM4E
SCHEMBL569756 0.84 DRD3 (0.54) MEN1KMT2AKLK7LCLAT1MAPT
SCHEMBL569406 0.84 LCLAT1 (0.44) MEN1KMT2AKLK7LCLAT1MAPT
SCHEMBL12473474 0.84 KMT2A (0.57) MEN1KMT2AKLK7LCLAT1MAPT
SCHEMBL10182454 0.84 MEN1 (0.47) MEN1KMT2AKLK7LCLAT1MAPT
SCHEMBL10182438 0.82 LCLAT1 (0.56) LCLAT1MAPTUSP2PTPN7KDM4E
SCHEMBL10182288 0.82 MEN1 (0.48) MEN1KMT2AKLK7LCLAT1MAPT
SCHEMBL569244 0.80 MAPT (0.43) MEN1KMT2AKLK7LCLAT1MAPT
SCHEMBL569245 0.78 KMT2A (0.41) MEN1KMT2AKLK7MAPTUSP2
SCHEMBL10182199 0.78 NPC1 (0.39) MEN1KMT2AMAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170152288-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY NOVALIX DEUTSCHLAND GMBH (DE) 2017-06-01 US disclosed
US-20170152288-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY NOVALIX DEUTSCHLAND GMBH (DE) 2017-06-01 US disclosed
EP-2601208-B1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2015-02-11 EP disclosed
US-20130131321-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2013-05-23 US disclosed
US-20130131321-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2013-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152288-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY FCGR1A, FCGR2A, FCGR3B MEN1 3656/4885KMT2A 2553/4885KLK7 551/4885
US-20130131321-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY FCGR1A, FCGR2A, FCER2 MEN1 3015/4885KMT2A 1127/4885KLK7 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.